Gilteritinib resistance management

After taking Gilitinib (Gilteritinib), if the patient develops drug resistance, a series of measures need to be taken to optimize the treatment plan to cope with the progression of the disease and changes in the patient's condition. First, doctors should evaluate the resistance in detail, including testing the patient's blood or bone marrow samples to confirm whether there are new changes in the FLT3 mutation or other related mutations. These examinations can help doctors understand the mechanism of drug resistance and guide subsequent treatment choices.

Once resistance is confirmed, doctors may consider changing treatment strategies. Generally speaking, other targeted drugs or chemotherapy options can be selected based on the patient's individual situation. For example, other treatments targeting FLT3 mutations, such as azacitidine or high-dose cytarabine, may be alternatives. At the same time, doctors can also explore the possibility of combination therapy, combining giritinib with other effective drugs to enhance the anti-tumor effect.

When patients encounter drug resistance, they need to be monitored regularly to observe the effectiveness of new treatment options and patient tolerance. This includes regular blood tests, imaging studies, and testing of relevant biomarkers so that treatment options can be adjusted in a timely manner. In addition, doctors pay attention to the patient's overall health, as well as any potential side effects, to ensure that the patient's quality of life is protected during treatment.

Finally, patients themselves should also actively participate in the treatment process and maintain good living habits, such as reasonable diet, appropriate exercise, adequate rest, etc., which will help improve the body's immunity and improve treatment effects. At the same time, patients should maintain close communication with doctors and provide timely feedback on their physical conditions and psychological feelings so that doctors can make corresponding adjustments and guidance.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC9872318/